vs
Orthofix Medical Inc.（OFIX）与LiveRamp Holdings, Inc.（RAMP）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是LiveRamp Holdings, Inc.的1.0倍（$219.9M vs $212.2M），LiveRamp Holdings, Inc.净利率更高（18.8% vs -1.0%，领先19.8%），LiveRamp Holdings, Inc.同比增速更快（8.6% vs 2.0%），过去两年LiveRamp Holdings, Inc.的营收复合增速更高（11.1% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
LiveRamp Holdings, Inc.是一家美国SaaS企业，核心业务为提供数据连接平台，服务涵盖数据导入、线下数据线上迁移等能力，助力企业开展营销相关的数据应用，为品牌及营销从业者的数字化运营提供技术支撑。
OFIX vs RAMP — 直观对比
营收规模更大
OFIX
是对方的1.0倍
$212.2M
营收增速更快
RAMP
高出6.6%
2.0%
净利率更高
RAMP
高出19.8%
-1.0%
两年增速更快
RAMP
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $212.2M |
| 净利润 | $-2.2M | $39.9M |
| 毛利率 | 71.1% | 71.9% |
| 营业利润率 | 0.2% | 18.6% |
| 净利率 | -1.0% | 18.8% |
| 营收同比 | 2.0% | 8.6% |
| 净利润同比 | 92.4% | 255.7% |
| 每股收益（稀释后） | $-0.05 | $0.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXRAMP
| Q4 25 | $219.9M | $212.2M | ||
| Q3 25 | $205.6M | $199.8M | ||
| Q2 25 | $203.1M | $194.8M | ||
| Q1 25 | $193.6M | $188.7M | ||
| Q4 24 | $215.7M | $195.4M | ||
| Q3 24 | $196.6M | $185.5M | ||
| Q2 24 | $198.6M | $176.0M | ||
| Q1 24 | $188.6M | $171.9M |
净利润OFIXRAMP
| Q4 25 | $-2.2M | $39.9M | ||
| Q3 25 | $-22.8M | $27.4M | ||
| Q2 25 | $-14.1M | $7.7M | ||
| Q1 25 | $-53.1M | $-6.3M | ||
| Q4 24 | $-29.1M | $11.2M | ||
| Q3 24 | $-27.4M | $1.7M | ||
| Q2 24 | $-33.4M | $-7.5M | ||
| Q1 24 | $-36.0M | $-5.4M |
毛利率OFIXRAMP
| Q4 25 | 71.1% | 71.9% | ||
| Q3 25 | 72.2% | 70.2% | ||
| Q2 25 | 68.7% | 70.1% | ||
| Q1 25 | 62.8% | 69.3% | ||
| Q4 24 | 69.0% | 71.9% | ||
| Q3 24 | 68.7% | 72.4% | ||
| Q2 24 | 67.8% | 70.6% | ||
| Q1 24 | 67.5% | 72.2% |
营业利润率OFIXRAMP
| Q4 25 | 0.2% | 18.6% | ||
| Q3 25 | -8.3% | 10.7% | ||
| Q2 25 | -7.9% | 3.7% | ||
| Q1 25 | -25.2% | -6.1% | ||
| Q4 24 | -5.3% | 7.5% | ||
| Q3 24 | -9.6% | 4.0% | ||
| Q2 24 | -12.5% | -3.0% | ||
| Q1 24 | -15.6% | -8.3% |
净利率OFIXRAMP
| Q4 25 | -1.0% | 18.8% | ||
| Q3 25 | -11.1% | 13.7% | ||
| Q2 25 | -6.9% | 4.0% | ||
| Q1 25 | -27.4% | -3.3% | ||
| Q4 24 | -13.5% | 5.7% | ||
| Q3 24 | -13.9% | 0.9% | ||
| Q2 24 | -16.8% | -4.3% | ||
| Q1 24 | -19.1% | -3.1% |
每股收益（稀释后）OFIXRAMP
| Q4 25 | $-0.05 | $0.62 | ||
| Q3 25 | $-0.57 | $0.42 | ||
| Q2 25 | $-0.36 | $0.12 | ||
| Q1 25 | $-1.35 | $-0.10 | ||
| Q4 24 | $-0.76 | $0.17 | ||
| Q3 24 | $-0.71 | $0.03 | ||
| Q2 24 | $-0.88 | $-0.11 | ||
| Q1 24 | $-0.95 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $403.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $962.3M |
| 总资产 | $850.6M | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXRAMP
| Q4 25 | $82.0M | $403.4M | ||
| Q3 25 | $62.9M | $376.9M | ||
| Q2 25 | $65.6M | $371.1M | ||
| Q1 25 | $58.0M | $420.8M | ||
| Q4 24 | $83.2M | $384.3M | ||
| Q3 24 | $30.1M | $348.4M | ||
| Q2 24 | $26.4M | $342.7M | ||
| Q1 24 | $27.0M | $368.9M |
总债务OFIXRAMP
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXRAMP
| Q4 25 | $450.0M | $962.3M | ||
| Q3 25 | $442.5M | $943.8M | ||
| Q2 25 | $458.3M | $947.8M | ||
| Q1 25 | $458.3M | $948.9M | ||
| Q4 24 | $503.1M | $957.7M | ||
| Q3 24 | $525.9M | $932.1M | ||
| Q2 24 | $546.0M | $951.9M | ||
| Q1 24 | $570.3M | $949.1M |
总资产OFIXRAMP
| Q4 25 | $850.6M | $1.3B | ||
| Q3 25 | $832.6M | $1.2B | ||
| Q2 25 | $837.2M | $1.2B | ||
| Q1 25 | $823.1M | $1.3B | ||
| Q4 24 | $893.3M | $1.3B | ||
| Q3 24 | $867.9M | $1.2B | ||
| Q2 24 | $882.0M | $1.2B | ||
| Q1 24 | $906.0M | $1.2B |
负债/权益比OFIXRAMP
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | — |
| 自由现金流经营现金流 - 资本支出 | $16.8M | — |
| 自由现金流率自由现金流/营收 | 7.6% | — |
| 资本支出强度资本支出/营收 | 4.9% | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXRAMP
| Q4 25 | $27.7M | — | ||
| Q3 25 | $12.4M | $57.4M | ||
| Q2 25 | $11.6M | $-15.8M | ||
| Q1 25 | $-18.4M | — | ||
| Q4 24 | $23.7M | $45.1M | ||
| Q3 24 | $11.7M | $55.6M | ||
| Q2 24 | $9.0M | $-9.3M | ||
| Q1 24 | $-18.6M | — |
自由现金流OFIXRAMP
| Q4 25 | $16.8M | — | ||
| Q3 25 | $2.5M | $56.8M | ||
| Q2 25 | $4.5M | $-16.2M | ||
| Q1 25 | $-25.1M | — | ||
| Q4 24 | $15.2M | $44.8M | ||
| Q3 24 | $6.3M | $55.4M | ||
| Q2 24 | $-360.0K | $-9.6M | ||
| Q1 24 | $-29.1M | — |
自由现金流率OFIXRAMP
| Q4 25 | 7.6% | — | ||
| Q3 25 | 1.2% | 28.4% | ||
| Q2 25 | 2.2% | -8.3% | ||
| Q1 25 | -13.0% | — | ||
| Q4 24 | 7.0% | 22.9% | ||
| Q3 24 | 3.2% | 29.8% | ||
| Q2 24 | -0.2% | -5.4% | ||
| Q1 24 | -15.4% | — |
资本支出强度OFIXRAMP
| Q4 25 | 4.9% | 0.1% | ||
| Q3 25 | 4.8% | 0.3% | ||
| Q2 25 | 3.5% | 0.2% | ||
| Q1 25 | 3.5% | 0.2% | ||
| Q4 24 | 4.0% | 0.1% | ||
| Q3 24 | 2.7% | 0.1% | ||
| Q2 24 | 4.7% | 0.1% | ||
| Q1 24 | 5.6% | 1.0% |
现金转化率OFIXRAMP
| Q4 25 | — | — | ||
| Q3 25 | — | 2.09× | ||
| Q2 25 | — | -2.04× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.02× | ||
| Q3 24 | — | 32.10× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
RAMP
暂无分部数据
